Precision Therapeutics Against Solid Cancers

Imprint

GANYMED Pharmaceuticals AG
Freiligrathstrasse 12

D-55131 Mainz

Amtsgericht Mainz, 90 HRB 7897
VAT ID-Nr.: DE 221960323

Phone:
Fax:

E-Mail:

+49 (0)6131 / 1440 - 100
+49 (0)6131 / 1440 - 114

info[at]ganymed-pharmaceuticals.com


Privacy Policy

GANYMED Pharmaceuticals AG fully respects the privacy of our website viewers. We recognize the need for appropriately protecting the personal information shared with us. If you choose to complete one of the forms on our web site with personal information, we will use the personal information only for the purpose that it was submitted, such as to consider your qualifications for potential employment or to respond to a specific inquiry.

GANYMED does not collect personal information for resale purposes or does share your information with any other company or organization.


Disclaimer

This web site is being set up by Ganymed Pharmaceuticals AG for use by viewers in connection with their interest in the company. Neither the company nor any of its affiliates, employees or representatives make any representation or warranty, expressed or implied, as to the accuracy or completeness of any of the information contained herein or any other information transmitted or made available to viewers, and each of such persons expressly disclaims any and all liability relating to or resulting from the use of this web site by viewers.


Forward Looking Statements

This web site contains "Forward Looking Statements". These projections presented in the web site represent subjective views of the management of GANYMED Pharmaceuticals AG and the management's current estimates of future performances based on various assumptions which the management believes are reasonable, but which may or may not prove to be correct. There can be no assurance that the management's views are accurate or that the management projections will be realized.


Third party links

On May 12, 1998, the District Court of Hamburg passed a decisive judgement that operating companies with a web site are responsible for the content of all Third Party Links to their original web site. Furthermore, the District Court of Hamburg states that operating companies are able to waiver all liability of the Third Party Linked web sites when it is explicitly stated in the original web site content that the operating company claims no responsibility for the Third Party Links and their content.

GANYMED Pharmaceuticals AG would like to explicitly state that it has no influence regarding the content and or quality of Third Party Links to the original Ganymed Pharmaceuticals AG web site. Therefore, Ganymed accepts no responsibility for Third Party Links to our entire web site or sub-pages.

News

[August 2010]

Clinical Phase I Results of GANYMED’s iMAB362 Antibody Demonstrate Excellent Safety

 

[April 2010]

ERNST & YOUNG, Deutscher Biotechnologie-Report 2010,

Das "Mainzer Modell": CI3

 

[Jan 2010]

34. Sendung TV-Magazin „in vivo“: vor Ort im Tumorvakzinationszentrum und bei Ganymed, Mainz (Deutsche Krebshilfe e. V.)

Conferences & Events

Meet us...

[September 2010]

European Cancer Cluster

Partnering, 15-17 sept. 2010,

(Folketeateret Oslo AS),

Oslo, Norway

[November 2010]

Bio-Europe 2010,

November 15-17, 2010

(International Congress Centre

Munich (ICM))

Cluster

Ganymed belongs to CI3 - Cluster of

"individualized immunointervention -

ImmunoPolis"

Associations

Association for Cancer Immunotherapy

Biotechnologie-Industrie-Organisation Deutschland e.V.

International Council for the Life Sciences